In addition to STING activation, the present study found that S100 monotherapy could upregulate the expression of Tim-3 in cDC2, subsequently diminishing the CD4+ T cell-mediated anti-tumor immunity; therefore, this negative impact could be relieved by αTim-3. This evidence concerns the gene STING1 and neoplasm.